 |
76 Diseases |  |
5 Trials |
|
5 Trials |  |
414 News |  |
| «123456 |
- || Rituxan (rituximab) / Roche
Trial primary completion date: Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan (clinicaltrials.gov) - Sep 28, 2014
P2, N=100, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2015 --> Jun 2016
- Arzerra (ofatumumab) / Novartis, Genmab
Trial primary completion date: Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma (clinicaltrials.gov) - Sep 12, 2014
P1, N=39, Recruiting, Sponsor: Thomas Jefferson University
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Jun 2014 --> Jun 2015
- Rituxan (rituximab) / Roche
Trial suspension, IO biomarker: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Jul 1, 2014
P2, N=46, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Suspended
- Rituxan (rituximab) / Roche
Enrollment change, Trial suspension, IO biomarker: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) - Jul 1, 2014
P2, N=46, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended N=74 --> 46 | Recruiting --> Suspended
- ||||| Rituxan (rituximab) / Roche
Enrollment change: Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov) - May 18, 2014
P3, N=172, Completed, Sponsor: US Oncology Research
N=74 --> 46 | Recruiting --> Suspended N=280 --> 172
- ||||||| Rituxan (rituximab) / Roche
Trial completion: Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov) - May 18, 2014
P3, N=172, Completed, Sponsor: US Oncology Research
N=280 --> 172 Active, not recruiting --> Completed
- SS1(dsFv)-PE38 / AstraZeneca
Enrollment open: SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma (clinicaltrials.gov) - May 15, 2014
P2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Recruiting
- SS1(dsFv)-PE38 / AstraZeneca
Enrollment change: SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma (clinicaltrials.gov) - May 15, 2014
P2, N=19, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting N=47 --> 19
- Rituxan (rituximab) / Roche
Trial completion date: Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - May 11, 2014
P2, N=45, Active, not recruiting, Sponsor: Mayo Clinic
N=47 --> 19 Trial completion date: Dec 2013 --> Dec 2014
- Rituxan (rituximab) / Roche
Trial primary completion date: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial completion date: Dec 2013 --> Dec 2014 Trial primary completion date: Jul 2014 --> May 2014
- Rituxan (rituximab) / Roche
Trial completion date: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial primary completion date: Jul 2014 --> May 2014 Trial completion date: Jul 2014 --> May 2014
- Rituxan (rituximab) / Roche
Enrollment change: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Trial completion date: Jul 2014 --> May 2014 N=63 --> 50
- Rituxan (rituximab) / Roche
Trial completion: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=50, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=63 --> 50 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Enrollment open: Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab (clinicaltrials.gov) - Apr 20, 2014
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Suspended --> Recruiting
- SS1(dsFv)-PE38 / AstraZeneca
Trial suspension: SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma (clinicaltrials.gov) - Apr 18, 2014
P2, N=19, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- ||| Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Roche
Enrollment change: Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 8, 2014
P2, N=68, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Suspended N=104 --> 68
- | Campath (alemtuzumab) / Sanofi
New P1/2 trial: Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure (clinicaltrials.gov) - Apr 3, 2014
P1/2, N=142, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- Campath (alemtuzumab) / Sanofi
Enrollment open: Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure (clinicaltrials.gov) - Apr 1, 2014
P1/2, N=142, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
N=104 --> 68 Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
Trial completion: Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Hoag Memorial Hospital Presbyterian
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | pentostatin / Generic mfg.
Trial completion: A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- busulfan / Generic mfg., pentostatin / Generic mfg.
Trial completion: Pento & tBU: Phase II Trial of Pentostatin and Targeted Busulfan (clinicaltrials.gov) - Jan 12, 2014
P2, N=42, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed: Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Nov 18, 2013
P2, N=45, Active, not recruiting, Sponsor: Niguarda Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Trial withdrawal: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Oct 13, 2013
P2, N=0, Withdrawn, Sponsor: University of Rochester
Recruiting --> Active, not recruiting Terminated --> Withdrawn
- Rituxan (rituximab) / Roche
Enrollment change: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease (clinicaltrials.gov) - Oct 13, 2013
P2, N=0, Withdrawn, Sponsor: University of Rochester
Terminated --> Withdrawn N=17 --> 0
- Rituxan (rituximab) / Roche
Trial suspension: Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 11, 2013
P2, N=49, Suspended, Sponsor: Memorial Sloan-Kettering Cancer Center
N=17 --> 0 Active, not recruiting --> Suspended
- Trial withdrawal: Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Nebraska
Active, not recruiting --> Suspended Terminated --> Withdrawn
- Enrollment change: Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Nebraska
Terminated --> Withdrawn N=20 --> 0
- | Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 7, 2013
P2, N=42, Active, not recruiting, Sponsor: Mayo Clinic
N=20 --> 0 Recruiting --> Active, not recruiting
- ||| Avastin (bevacizumab) / Roche, Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Jan 31, 2013
P2, N=104, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial termination: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2013
P2, N=6, Terminated, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Slow accrual
- Enrollment change: Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 6, 2013
P2, N=6, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; Slow accrual N=36 --> 6
- ||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed, IO biomarker: Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Nov 26, 2012
P2, N=82, Active, not recruiting, Sponsor: Mayo Clinic
N=36 --> 6 Recruiting --> Active, not recruiting
- Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=63, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Arzerra (ofatumumab) / Novartis, Genmab
New P2 trial: Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 6, 2012
P2, N=45, Active, not recruiting, Sponsor: Niguarda Hospital
- Enbrel (etanercept) / Pfizer, Amgen, Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion, Combination therapy: BMTCTN0302: Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) (clinicaltrials.gov) - Jun 24, 2012
P2, N=180, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- cordycepin (OVI-123) / OncoVista
Enrollment change: Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jun 11, 2012
P1, N=14, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed N=30 --> 14
- cordycepin (OVI-123) / OncoVista
Trial completion: Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jun 11, 2012
P1, N=14, Completed, Sponsor: Boston Medical Center
N=30 --> 14 Active, not recruiting --> Completed
- pentostatin / Generic mfg.
Enrollment change: Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Feb 21, 2012
P3, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=165 --> 6
- pentostatin / Generic mfg.
Trial completion: Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Feb 21, 2012
P3, N=6, Completed, Sponsor: St. Jude Children's Research Hospital
N=165 --> 6 Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Enrollment change, Metastases: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer (clinicaltrials.gov) - Jan 8, 2012
P1/2, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=72 --> 54
- pentostatin / Generic mfg.
Enrollment change: Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease (clinicaltrials.gov) - Nov 14, 2011
P2, N=8, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
N=72 --> 54 N=46 --> 8
- ||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment change, IO biomarker: Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Aug 24, 2011
P2, N=82, Active, not recruiting, Sponsor: Mayo Clinic
N=46 --> 8 N=48 --> 82
- Rituxan (rituximab) / Roche
New P1 trial: Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab (clinicaltrials.gov) - Aug 11, 2011
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- pentostatin / Generic mfg.
Enrollment closed: Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease (clinicaltrials.gov) - Aug 7, 2011
P2, N=8, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
N=48 --> 82 Suspended --> Active, not recruiting